Suzanne F Bradley1. 1. Internal Medicine, Divisions of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, US.
Abstract
INTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) contains a gene that makes it resistant to methicillin as well as to other beta-lactam antibiotics, including flucloxacillin, cephalosporins, and carbapenems. MRSA can be part of the normal body flora (colonisation), especially in the nose, but it can cause infection. Until recently, MRSA has primarily been a problem associated with exposure to the healthcare system, especially in people with prolonged hospital admissions or underlying disease, or after antibiotic use. In many countries worldwide, a preponderance of S aureus bloodstream isolates are resistant to methicillin. METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical question: What are the effects of treatment for MRSA nasal or extra-nasal colonisation in adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2014 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview). RESULTS: At this update, searching of electronic databases retrieved 850 studies. After deduplication and removal of conference abstracts, 356 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 273 studies, and the further review of 83 full publications. Of the 83 full articles evaluated, no studies were added at this update. We performed a GRADE evaluation for three PICO combinations. CONCLUSIONS: In this systematic overview, we categorised the efficacy for five interventions based on information about the effectiveness and safety of antiseptic body washes, chlorhexidine-neomycin nasal cream, mupirocin nasal ointment, systemic antimicrobials, and other topical antimicrobials.
INTRODUCTION:Methicillin-resistant Staphylococcus aureus (MRSA) contains a gene that makes it resistant to methicillin as well as to other beta-lactam antibiotics, including flucloxacillin, cephalosporins, and carbapenems. MRSA can be part of the normal body flora (colonisation), especially in the nose, but it can cause infection. Until recently, MRSA has primarily been a problem associated with exposure to the healthcare system, especially in people with prolonged hospital admissions or underlying disease, or after antibiotic use. In many countries worldwide, a preponderance of S aureus bloodstream isolates are resistant to methicillin. METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical question: What are the effects of treatment for MRSA nasal or extra-nasal colonisation in adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2014 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview). RESULTS: At this update, searching of electronic databases retrieved 850 studies. After deduplication and removal of conference abstracts, 356 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 273 studies, and the further review of 83 full publications. Of the 83 full articles evaluated, no studies were added at this update. We performed a GRADE evaluation for three PICO combinations. CONCLUSIONS: In this systematic overview, we categorised the efficacy for five interventions based on information about the effectiveness and safety of antiseptic body washes, chlorhexidine-neomycin nasal cream, mupirocin nasal ointment, systemic antimicrobials, and other topical antimicrobials.
Authors: David P Calfee; Cassandra D Salgado; David Classen; Kathleen M Arias; Kelly Podgorny; Deverick J Anderson; Helen Burstin; Susan E Coffin; Erik R Dubberke; Victoria Fraser; Dale N Gerding; Frances A Griffin; Peter Gross; Keith S Kaye; Michael Klompas; Evelyn Lo; Jonas Marschall; Leonard A Mermel; Lindsay Nicolle; David A Pegues; Trish M Perl; Sanjay Saint; Robert A Weinstein; Robert Wise; Deborah S Yokoe Journal: Infect Control Hosp Epidemiol Date: 2008-10 Impact factor: 3.254
Authors: Marlieke E A de Kraker; Martin Wolkewitz; Peter G Davey; Walter Koller; Jutta Berger; Jan Nagler; Claudine Icket; Smilja Kalenic; Jasminka Horvatic; Harald Seifert; Achim J Kaasch; Olga Paniara; Athina Argyropoulou; Maria Bompola; Edmond Smyth; Mairead Skally; Annibale Raglio; Uga Dumpis; Agita Melbarde Kelmere; Michael Borg; Deborah Xuereb; Mihaela C Ghita; Michelle Noble; Jana Kolman; Stanko Grabljevec; David Turner; Louise Lansbury; Hajo Grundmann Journal: Antimicrob Agents Chemother Date: 2011-01-10 Impact factor: 5.191
Authors: Heidi S M Ammerlaan; Jan A J W Kluytmans; Heiman F L Wertheim; Jan L Nouwen; Marc J M Bonten Journal: Clin Infect Dis Date: 2009-04-01 Impact factor: 9.079
Authors: Lona Mody; Carol A Kauffman; Shelly A McNeil; Andrzej T Galecki; Suzanne F Bradley Journal: Clin Infect Dis Date: 2003-11-06 Impact factor: 9.079
Authors: C Wendt; S Schinke; M Württemberger; K Oberdorfer; O Bock-Hensley; H von Baum Journal: Infect Control Hosp Epidemiol Date: 2007-07-03 Impact factor: 3.254
Authors: Dingyi Yang; Yin Xin Ho; Laura M Cowell; Iqra Jilani; Simon J Foster; Lynne R Prince Journal: Front Immunol Date: 2019-01-31 Impact factor: 7.561